Generic name: perflutren (per FLOO tren)
Brand name: Definity, Optison
Dosage forms: intravenous suspension ((lipid microspheres); (protein-type A microspheres))
Drug class: Ultrasound contrast media
What is perflutren?
Perflutren is an ultrasound contrast agent that is used to improve the quality of an echocardiogram (ultrasound of the heart). Perflutren works by changing the way ultrasound waves travel within your heart. This helps the ultrasound portray a sharper image of your heart.
Perflutren is used to allow certain segments of the heart to be seen more clearly on an echocardiogram.
Perflutren may also be used for purposes not listed in this medication guide.
Serious side effects may occur during the injection. Tell your caregiver if you feel dizzy, nauseated, light-headed, short of breath, or if you have a severe headache, pounding in your ears, chest pain, fast or slow heartbeats, wheezing, or shallow breathing.
You should not be treated with perflutren if you have a genetic heart condition called "cardiac shunt."
Before taking this medicine
You should not be treated with perflutren if you are allergic to it, or if you have:
a genetic heart condition called "cardiac shunt"; or
if you are allergic to blood products or to a medicine that contains albumin.
Tell your doctor if you have ever had:
a congenital heart defect;
a lung condition that has recently become worse; or
if you have ever had an allergic reaction during a blood transfusion.
Perflutren is made from donated human plasma and may contain viruses or other infectious agents. Donated plasma is tested and treated to reduce the risk of contamination, but there is still a small possibility it could transmit disease. Ask your doctor about any possible risk.
Tell your doctor if you are pregnant.
If you are breastfeeding a baby, use a breast pump to empty your milk supply one time after you are treated with perflutren. Throw out the milk you collect during this time and do not feed it to your baby.
How is perflutren given?
Perflutren is given as an infusion into a vein. A healthcare provider will give you this injection just before the start of your echocardiogram.
Your heart rate, breathing, blood pressure, oxygen levels, and other vital signs will be watched closely for at least 30 minutes after you receive perflutren. This is to make sure you do not have an allergic reaction to the medicine.
What happens if I miss a dose?
Since perflutren is given with an echocardiogram, you will not be on a regular dosing schedule.
What happens if I overdose?
Since perflutren is given by a healthcare professional in a medical setting, an overdose is unlikely to occur.
What should I avoid after receiving perflutren?
Follow your doctor's instructions about any restrictions on food, beverages, or activity.
Perflutren side effects
Get emergency medical help if you have signs of an allergic reaction: hives, skin redness, itching; warmth, redness, numbness, or tingly feeling; wheezing, trouble breathing, tightness in your chest or throat; swelling of your face, lips, tongue, or throat.
In rare cases, serious or fatal reactions may occur during the injection or shortly afterward. Tell your caregivers right away if you have:
a light-headed feeling, like you might pass out;
severe dizziness, or a cold sweat;
chest pain, wheezing, trouble breathing;
fast or slow heartbeats;
severe headache, blurred vision, pounding in your neck or ears, anxiety, confusion; or
slow heart rate, weak pulse, fainting, weak or shallow breathing.
You may be more likely to have a serious reaction if you have severe or uncontrolled heart problems (congestive heart failure, a recent heart attack, serious heart rhythm disorder).
Common side effects may include:
flushing (warmth, redness, or tingly feeling);
pain in your side or lower back; or
pain, swelling, or irritation where the injection was given.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Perflutren dosing information
Usual Adult Dose for Echocardiography:
-Administer by IV bolus or IV infusion immediately after activation in the VIALMIX(R) apparatus; if more than 5 minutes elapses before use, resuspend with 10 seconds of hand agitation.
-Administer 10 microL/kg IV bolus; follow with a 10 mL saline flush.
-If necessary, a second 10 microL/kg IV bolus (followed with a 10 mL saline flush) may be administered 30 minutes later to prolong contrast enhancement.
-Maximum dose: 2 bolus doses
-Prepare an IV infusion by adding 1.3 mL activated Definity(R) suspension to 50 mL of preservative-free saline.
-Begin IV infusion at 4 mL/minute; may titrate up to 10 mL/minute to achieve optimal image enhancement.
-Maximum Infusion Rate: 10 mL/minute
-Maximum Dose: One IV infusion
Comments: The safety of bolus and infusion dosing in combination or in sequence has not been studied.
-Dose should be individualized taking into account body habitus, intervening lung tissue, adequacy of transducer skin interface, and other acoustic factors.
-Time from resuspension to injection should not exceed 1 minute, if time is exceeded, resuspend the microspheres.
-Initial dose: 0.5 mL IV into peripheral vein at a rate not to exceed 1 mL per second; follow with a flush of NS or D5W.
-Additional doses in increments of 0.5 mL up to a cumulative dose of 5 mL in a 10 minute period may be administered if contrast enhancement is inadequate.
-Maximum dose per study: 8.7 mL
Use: As an ultrasound contrast agent to opacify the left ventricular chamber and improve the delineation of the left ventricular endocardial borders in patients with suboptimal echocardiograms.
What other drugs will affect perflutren?
Other drugs may affect perflutren, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.
More about perflutren
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Interactions
- En Español
- 2 Reviews
- Drug class: ultrasound contrast media
- Advanced Reading
- Perflutren protein type a microsphere Intravenous (Advanced Reading)
- Perflutren Lipid Microspheres
- Perflutren Protein Type A
Related treatment guides
Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Copyright 1996-2022 Cerner Multum, Inc. Version: 4.01.